Newman Dignan & Sheerar Inc. Reduces Stock Holdings in Danaher Co. (NYSE:DHR)

Newman Dignan & Sheerar Inc. decreased its position in Danaher Co. (NYSE:DHR) by 5.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,328 shares of the conglomerate’s stock after selling 270 shares during the period. Newman Dignan & Sheerar Inc.’s holdings in Danaher were worth $993,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of DHR. FMR LLC lifted its stake in Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares during the last quarter. Van ECK Associates Corp lifted its stake in Danaher by 6,862.7% in the fourth quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock valued at $213,452,000 after purchasing an additional 916,513 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Danaher by 40,196.5% in the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after purchasing an additional 428,897 shares during the last quarter. Finally, Montrusco Bolton Investments Inc. lifted its stake in Danaher by 30.4% in the third quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after purchasing an additional 397,671 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE:DHR opened at $206.66 on Friday. The business has a 50 day moving average of $229.53 and a 200 day moving average of $249.51. The company has a market capitalization of $149.26 billion, a price-to-earnings ratio of 39.14, a PEG ratio of 2.68 and a beta of 0.83. Danaher Co. has a 1-year low of $196.80 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.

Danaher (NYSE:DHR) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the business posted $2.09 earnings per share. On average, sell-side analysts predict that Danaher Co. will post 7.67 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were given a $0.27 dividend. The ex-dividend date was Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.52%. Danaher’s payout ratio is currently 20.45%.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on DHR shares. Robert W. Baird dropped their target price on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. UBS Group dropped their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. dropped their target price on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Finally, Wells Fargo & Company dropped their target price on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Seven equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.